Literature DB >> 12960342

Successful induction of CD8 T cell-dependent protection against malaria by sequential immunization with DNA and recombinant poxvirus of neonatal mice born to immune mothers.

Martha Sedegah1, Maria Belmonte, Judith E Epstein, Claire-Anne Siegrist, Walter R Weiss, Trevor R Jones, Minh Lu, Daniel J Carucci, Stephen L Hoffman.   

Abstract

In some parts of Africa, 50% of deaths attributed to malaria occur in infants less than 8 mo. Thus, immunization against malaria may have to begin in the neonatal period, when neonates have maternally acquired Abs against malaria parasite proteins. Many malaria vaccines in development rely upon CD8 cells as immune effectors. Some studies indicate that neonates do not mount optimal CD8 cell responses. We report that BALB/c mice first immunized as neonates (7 days) with a Plasmodium yoelii circumsporozoite protein (PyCSP) DNA vaccine mixed with a plasmid expressing murine GM-CSF (DG) and boosted at 28 days with poxvirus expressing PyCSP were protected (93%) as well as mice immunized entirely as adults (70%). Protection was dependent on CD8 cells, and mice had excellent anti-PyCSP IFN-gamma and cytotoxic T lymphocyte responses. Mice born of mothers previously exposed to P. yoelii parasites or immunized with the vaccine were protected and had excellent T cell responses. These data support assessment of this immunization strategy in neonates/young infants in areas in which malaria exacts its greatest toll.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12960342     DOI: 10.4049/jimmunol.171.6.3148

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

Review 1.  Genetic vaccination approaches against malaria based on the circumsporozoite protein.

Authors:  Sandra Scheiblhofer; Richard Weiss; Josef Thalhamer
Journal:  Wien Klin Wochenschr       Date:  2006       Impact factor: 1.704

Review 2.  Dissecting the defects in the neonatal CD8+ T-cell response.

Authors:  Adam J Fike; Ogan K Kumova; Alison J Carey
Journal:  J Leukoc Biol       Date:  2019-07-01       Impact factor: 4.962

3.  Mucosally delivered Salmonella live vector vaccines elicit potent immune responses against a foreign antigen in neonatal mice born to naive and immune mothers.

Authors:  Alejandra V E Capozzo; Lilian Cuberos; Myron M Levine; Marcela F Pasetti
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

4.  Plasmodium falciparum-specific cellular immune responses after immunization with the RTS,S/AS02D candidate malaria vaccine in infants living in an area of high endemicity in Mozambique.

Authors:  Arnoldo Barbosa; Denise Naniche; John J Aponte; M Nelia Manaca; Inacio Mandomando; Pedro Aide; Jahit Sacarlal; Montse Renom; Sarah Lafuente; W Ripley Ballou; Pedro L Alonso
Journal:  Infect Immun       Date:  2009-08-03       Impact factor: 3.441

5.  Maternal LAMP/p55gagHIV-1 DNA immunization induces in utero priming and a long-lasting immune response in vaccinated neonates.

Authors:  Paula Ordonhez Rigato; Milton Maciel; Adriana Letícia Goldoni; Orlando Guerra Piubelli; Noemia Mie Orii; Ernesto Torres Marques; Joseph Thomas August; Alberto José da Silva Duarte; Maria Notomi Sato
Journal:  PLoS One       Date:  2012-02-15       Impact factor: 3.240

6.  Delivery of SA35 and SA40 peptides in mice enhances humoral and cellular immune responses and confers protection against Cryptosporidium parvum infection.

Authors:  Fabio Tosini; Alessandra Ludovisi; Daniele Tonanzi; Marco Amati; Simona Cherchi; Edoardo Pozio; Maria Angeles Gómez-Morales
Journal:  Parasit Vectors       Date:  2019-05-15       Impact factor: 3.876

7.  LAMP-1 Chimeric to HIV-1 p55Gag in the Immunization of Neonate Mice Induces an Early Germinal Center Formation and AID Expression.

Authors:  Franciane Mouradian Emidio Teixeira; Luana de Mendonça Oliveira; Anna Julia Pietrobon; Érika Machado de Salles; Maria Regina D'Império Lima; Isabelle Freire Tabosa Viana; Roberto Dias Lins; Paula Ordonhez Rigato; Ernesto Torres de Azevedo Marques; Alberto José da Silva Duarte; Maria Notomi Sato
Journal:  Vaccines (Basel)       Date:  2022-08-03

8.  Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA.

Authors:  Thomas L Richie; Yupin Charoenvit; Ruobing Wang; Judith E Epstein; Richard C Hedstrom; Sanjai Kumar; Thomas C Luke; Daniel A Freilich; Joao C Aguiar; John B Sacci; Martha Sedegah; Ronald A Nosek; Patricia De La Vega; Mara P Berzins; Victoria F Majam; Esteban N Abot; Harini Ganeshan; Nancy O Richie; Jo Glenna Banania; Maria Fe B Baraceros; Tanya G Geter; Robin Mere; Lolita Bebris; Keith Limbach; Bradley W Hickey; David E Lanar; Jennifer Ng; Meng Shi; Peter M Hobart; Jon A Norman; Lorraine A Soisson; Michael R Hollingdale; William O Rogers; Denise L Doolan; Stephen L Hoffman
Journal:  Hum Vaccin Immunother       Date:  2012-11-01       Impact factor: 3.452

9.  DNA vaccines: designing strategies against parasitic infections.

Authors:  Catherine Ivory; Kris Chadee
Journal:  Genet Vaccines Ther       Date:  2004-12-03

10.  Fusion of antigen to a dendritic cell targeting chemokine combined with adjuvant yields a malaria DNA vaccine with enhanced protective capabilities.

Authors:  Kun Luo; Hong Zhang; Fidel Zavala; Arya Biragyn; Diego A Espinosa; Richard B Markham
Journal:  PLoS One       Date:  2014-03-05       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.